Maaike van der Lee

497 total citations
22 papers, 293 citations indexed

About

Maaike van der Lee is a scholar working on Pharmacology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Maaike van der Lee has authored 22 papers receiving a total of 293 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pharmacology, 6 papers in Molecular Biology and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Maaike van der Lee's work include Pharmacogenetics and Drug Metabolism (16 papers), Genomics and Rare Diseases (4 papers) and Drug Transport and Resistance Mechanisms (4 papers). Maaike van der Lee is often cited by papers focused on Pharmacogenetics and Drug Metabolism (16 papers), Genomics and Rare Diseases (4 papers) and Drug Transport and Resistance Mechanisms (4 papers). Maaike van der Lee collaborates with scholars based in Netherlands, Germany and France. Maaike van der Lee's co-authors include Jesse J. Swen, Henk‐Jan Guchelaar, Marjolein Kriek, Seyed Yahya Anvar, Roberta Menafra, Teun van Gelder, William J. Rowell, Stefano Gastaldello, Gijs W.E. Santen and Mariëtte J.V. Hoffer and has published in prestigious journals such as Science Translational Medicine, The Annual Review of Pharmacology and Toxicology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Maaike van der Lee

21 papers receiving 284 citations

Peers

Countries citing papers authored by Maaike van der Lee

Since Specialization

Citations

This map shows the geographic impact of Maaike van der Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maaike van der Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maaike van der Lee more than expected).

Fields of papers citing papers by Maaike van der Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maaike van der Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maaike van der Lee. The network helps show where Maaike van der Lee may publish in the future.

Co-authorship network of co-authors of Maaike van der Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Maaike van der Lee. A scholar is included among the top collaborators of Maaike van der Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maaike van der Lee. Maaike van der Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects 2025 ·Clinical Pharmacology & Therapeutics ·(unknown), Eugène T.P. Verwiel, Maaike van der Lee, Jesse J. Swen, (unknown), (unknown), Rick Admiraal, Bastiaan B.J. Tops, Alwin D. R. Huitema, Patrick Kemmeren, Jayne Y. Hehir‐Kwa, Lidwien M. Hanff, (unknown)	1
2	A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development 2025 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), (unknown), (unknown), (unknown), Dominik Selzer, Donato Teutonico, (unknown), Juri Solodenko, Sebastian Frechen, Maaike van der Lee, Dirk Jan A. R. Moes, Jesse J. Swen, Matthias Schwab, Thorsten Lehr	3
3	Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account 2025 ·Clinical Pharmacology & Therapeutics ·Inger Johansson, (unknown), Yitian Zhou, (unknown), Maaike van der Lee, (unknown), Elisabet Størset, Jesse J. Swen, Henk‐Jan Guchelaar, Espen Molden, Marin M. Jukić, Magnus Ingelman‐Sundberg	0
4	Pharmacogenetic Panel Testing: A Review of Current Practice and Potential for Clinical Implementation 2024 ·The Annual Review of Pharmacology and Toxicology ·(unknown), Maaike van der Lee, Henk‐Jan Guchelaar, Jesse J. Swen	4
5	Addendum To: Study protocol of the HD-MED study aiming to personalize drug treatment in Huntington’s disease: a longitudinal, observational study to assess medication use and efficacy in relation to pharmacogenetics 2024 ·PubMed Central ·(unknown), Maaike van der Lee, Jesse J. Swen, Raymund A.C. Roos, Susanne T. de Bot	1
6	The effect of genetic variants in the transcription factor TSPYL family on the CYP3A4 mediated cyclosporine metabolism in kidney transplant patients 2024 ·Clinical and Translational Science ·(unknown), Dirk Jan A. R. Moes, Teun van Gelder, Maaike van der Lee, Jan‐Stephan Sanders, Fréderike J. Bemelman, Johan W. de Fijter, Kathrin Klein, Matthias Schwab, Jesse J. Swen	3
7	Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug–drug–gene interaction network 2023 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), (unknown), (unknown), Dominik Selzer, (unknown), Donato Teutonico, Sebastian Frechen, Maaike van der Lee, Dirk Jan A. R. Moes, Jesse J. Swen, Matthias Schwab, Thorsten Lehr	9
8	Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions 2023 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), (unknown), (unknown), Dominik Selzer, Matthias Schwab, Donato Teutonico, Sebastian Frechen, Maaike van der Lee, Dirk Jan A. R. Moes, Jesse J. Swen, Thorsten Lehr	11
9	From gene to dose: Long-read sequencing and -allele tools to refine phenotype predictions of CYP2C19 2023 ·Frontiers in Pharmacology* ·(unknown), (unknown), (unknown), Roberta Menafra, (unknown), Susan L. Kloet, Maaike van der Lee	8
10	Study protocol of the HD-MED study aiming to personalize drug treatment in Huntington’s disease: a longitudinal, observational study to assess medication use and efficacy in relation to pharmacogenetics 2023 ·PubMed ·(unknown), Maaike van der Lee, Jesse J. Swen, Raymund A.C. Roos, Susanne T. de Bot	2
11	Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity 2022 ·Frontiers in Pharmacology ·(unknown), Maaike van der Lee, Teun van Gelder, Jesse J. Swen	19
12	Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: lessons from a pilot study on 100 whole exome sequencing data 2022 ·The Pharmacogenomics Journal ·Alireza Tafazoli, Maaike van der Lee, Jesse J. Swen, A. Zeller, Natalia Wawrusiewicz‐Kurylonek, Hailiang Mei, Ruben H.P. Vorderman, (unknown), (unknown), Wojciech Miltyk	7
13	Artificial intelligence in pharmacology research and practice 2022 ·Clinical and Translational Science ·Maaike van der Lee, Jesse J. Swen	45
14	Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data 2021 ·Science Translational Medicine ·Maaike van der Lee, (unknown), Rolf H. A. M. Vossen, Renée Baak-Pablo, Roberta Menafra, Birgit Deiman, Maarten J. Deenen, Patrick Neven, Inger Johansson, Stefano Gastaldello, Magnus Ingelman‐Sundberg, Henk‐Jan Guchelaar, Jesse J. Swen, Seyed Yahya Anvar	45
15	Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle 2021 ·The Pharmacogenomics Journal ·Maaike van der Lee, William J. Rowell, Roberta Menafra, Henk‐Jan Guchelaar, Jesse J. Swen, Seyed Yahya Anvar	21
16	Substrate Specificity of CYP2D6 Genetic Variants 2021 ·Pharmacogenomics ·Maaike van der Lee, Henk‐Jan Guchelaar, Jesse J. Swen	19
17	Technologies for Pharmacogenomics: A Review 2020 ·Genes ·Maaike van der Lee, Marjolein Kriek, Henk‐Jan Guchelaar, Jesse J. Swen	36
18	Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics 2019 ·Clinical Pharmacology & Therapeutics ·Maaike van der Lee, (unknown), Sander Bollen, Gijs W.E. Santen, Claudia Ruivenkamp, Mariëtte J.V. Hoffer, Marjolein Kriek, Henk‐Jan Guchelaar, Seyed Yahya Anvar, Jesse J. Swen	30
19	Patterns of topical corticosteroids prescriptions in children with asthma 2018 ·Pediatric Dermatology ·(unknown), Susanne J. H. Vijverberg, Maaike van der Lee, Cornelis K. van der Ent, Carla A.F.M. Bruijnzeel-Koomen, Marjolein de Bruin‐Weller, Jan A. M. Raaijmakers, Anke H. Maitland‐van der Zee	1
20	Atopic dermatitis characteristics and medication-use patterns in school-age children with AD and asthma symptoms 2017 ·Clinical and Experimental Dermatology ·Maaike van der Lee, (unknown), Francine C. van Erp, J. A. M. Raaijmakers, Cornelis K. van der Ent, Carla A.F.M. Bruijnzeel-Koomen, Marjolein de Bruin‐Weller, Susanne J. H. Vijverberg, Anke H. Maitland‐van der Zee	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact